$OCGN
Ocugen, Inc. Stock $ocgn

$ocgn Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000162828020007094 Filed on May 08, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue		$900.0K
YoY Change
Gross Profit		-$900.0K
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.280M	$2.930M
YoY Change	-22.18%	4.27%
% of Gross Profit
Research & Development	$1.652M	$3.793M
YoY Change	-56.44%	15.43%
% of Gross Profit
Depreciation & Amortization	$18.00K	$14.60K
YoY Change	23.25%	-91.51%
% of Gross Profit
Operating Expenses	$3.929M	$4.841M
YoY Change	-18.84%	-20.55%
Operating Profit	-$3.929M	-$4.841M
YoY Change	-18.84%	-20.55%
Interest Expense	$15.00K	$695.5K
YoY Change	-97.84%	1779.65%
% of Operating Profit
Other Income/Expense, Net	-$15.00K	-$1.472M
YoY Change	-98.98%	-83.16%
Pretax Income	-$3.940M	-$9.420M
YoY Change	-58.17%	-36.48%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$3.944M	-$6.313M
YoY Change	-37.52%	-57.44%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$74.86K	-$7.030M
COMMON SHARES
Basic Shares Outstanding	52.63M shares	94.60M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.190M	$7.380M
YoY Change	-56.78%	-52.42%
Cash & Equivalents	$3.193M	$308.7K
Short-Term Investments
Other Short-Term Assets	$8.170M	$760.0K
YoY Change	975.0%	-11.63%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$11.36M	$8.140M
YoY Change	39.59%	-50.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$249.0K	$135.0K
YoY Change	84.44%	-96.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$551.2K	$6.426M
YoY Change	-91.42%	1160.0%
Total Long-Term Assets	$951.3K	$6.698M
YoY Change	-85.8%	35.04%
TOTAL ASSETS
Total Short-Term Assets	$11.36M	$8.140M
Total Long-Term Assets	$951.3K	$6.698M
Total Assets	$12.31M	$14.84M
YoY Change	-17.01%	-30.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.548M	$1.100M
YoY Change	40.76%	-19.12%
Accrued Expenses	$1.384M	$99.00K
YoY Change	1297.63%	-94.31%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.315M	$2.317M
YoY Change	43.07%	-72.48%
LONG-TERM LIABILITIES
Long-Term Debt	$1.581M	$0.00
YoY Change
Other Long-Term Liabilities	$3.940K	$18.05M
YoY Change	-99.98%	-45.27%
Total Long-Term Liabilities	$1.702M	$18.05M
YoY Change	-90.57%	-45.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.315M	$2.317M
Total Long-Term Liabilities	$1.702M	$18.05M
Total Liabilities	$5.017M	$20.37M
YoY Change	-75.37%	-50.8%
SHAREHOLDERS EQUITY
Retained Earnings	-$55.40M	-$226.2M
YoY Change	-75.51%
Common Stock	$527.5K	$220.7M
YoY Change	-99.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$47.86K
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.297M	-$18.61M
YoY Change
Total Liabilities & Shareholders Equity	$12.31M	$14.84M
YoY Change	-17.01%	-30.44%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$3.944M	-$6.313M
YoY Change	-37.52%	-57.44%
Depreciation, Depletion And Amortization	$18.00K	$14.60K
YoY Change	23.25%	-91.51%
Cash From Operating Activities	-$4.686M	-$2.667M
YoY Change	75.69%	-181.17%
INVESTING ACTIVITIES
Capital Expenditures	$53.00K	$10.58K
YoY Change	400.9%	-99.16%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$53.00K	-$10.58K
YoY Change	400.9%	-97.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$488.0K	$1.359M
YoY Change	-64.09%	-75.27%
NET CHANGE
Cash From Operating Activities	-$4.686M	-$2.667M
Cash From Investing Activities	-$53.00K	-$10.58K
Cash From Financing Activities	$488.0K	$1.359M
Net Change In Cash	-$4.251M	-$1.319M
YoY Change	222.22%	-115.66%
FREE CASH FLOW
Cash From Operating Activities	-$4.686M	-$2.667M
Capital Expenditures	$53.00K	$10.58K
Free Cash Flow	-$4.739M	-$2.678M
YoY Change	76.97%	-231.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001372299
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-36751
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	OCUGEN, INC.
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3522315
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5 Great Valley Parkway
CY2020Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 160
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Malvern
CY2020Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19355
CY2020Q1	dei	City Area Code CityAreaCode	484
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	328-4701
CY2020Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2020Q1	dei	Trading Symbol TradingSymbol	OCGN
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74549048	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3193188	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7444052	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1169297	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1322167	USD
CY2020Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	7000000	USD
CY2019Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	7000000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	11362485	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	15766219	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	248997	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	222464	USD
CY2020Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151100	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151016	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	551163	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	667747	USD
CY2020Q1	us-gaap	Assets Assets	12313745	USD
CY2019Q4	us-gaap	Assets Assets	16807446	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1548309	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1895613	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1383658	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2270045	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	176616	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	172310	USD
CY2020Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	206415	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	205991	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3314998	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4543959	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	117142	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	163198	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1580560	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1072123	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3940	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9755	USD
CY2020Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1701642	USD
CY2019Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1245076	USD
CY2020Q1	us-gaap	Liabilities Liabilities	5016640	USD
CY2019Q4	us-gaap	Liabilities Liabilities	5789035	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	7	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	7	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	7	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	7	shares
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52746728	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52746728	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52625228	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52625228	shares
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	527467	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	527467	USD
CY2020Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	121500	shares
CY2019Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	121500	shares
CY2020Q1	us-gaap	Treasury Stock Value TreasuryStockValue	47864	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	47864	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	62241145	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	62018632	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55423643	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12313745	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16807446	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51479824	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	7297105	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	11018411	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1652318	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3793022	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2276784	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1048020	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	3929102	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	4841042	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3929102	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4841042	USD
CY2019Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-776273	USD
CY2020Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	119	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	594	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	14749	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	695469	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-87	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-416	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-14717	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1471564	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-3943819	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-6312606	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.27
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52627228	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4960552	shares
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-282	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3943819	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6312888	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	11018411	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	222513	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-3943819	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	7297105	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-12709539	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	415202	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-282	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-6312606	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	-18607225	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-3943819	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-6312606	USD
CY2020Q1	us-gaap	Depreciation Depreciation	18283	USD
CY2020Q1	ocgn	Non Cash Interest Expense NonCashInterestExpense	14749	USD
CY2019Q1	us-gaap	Depreciation Depreciation	14604	USD
CY2019Q1	ocgn	Non Cash Interest Expense NonCashInterestExpense	695469	USD
CY2020Q1	ocgn	Noncash Lease Expense NoncashLeaseExpense	47696	USD
CY2019Q1	ocgn	Noncash Lease Expense NoncashLeaseExpense	73273	USD
CY2020Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2019Q1	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-776273	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	222513	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	415202	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-227870	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-49555	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1225853	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1723507	USD
CY2020Q1	ocgn	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	-47862	USD
CY2019Q1	ocgn	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	-102488	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4686423	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2667211	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	52653	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10581	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-52653	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10581	USD
CY2020Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5964	USD
CY2019Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	5964	USD
CY2020Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	5740	USD
CY2019Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	85233	USD
CY2020Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	500000	USD
CY2019Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	1450000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	488296	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1358803	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-282	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4250780	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1319271	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7595068	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1778613	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3344288	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	459342	USD
CY2020Q1	ocgn	Noncash Or Part Noncash Operating Lease Right Of Use Asset NoncashOrPartNoncashOperatingLeaseRightOfUseAsset	0	USD
CY2019Q1	ocgn	Noncash Or Part Noncash Operating Lease Right Of Use Asset NoncashOrPartNoncashOperatingLeaseRightOfUseAsset	427751	USD
CY2020Q1	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen, Inc. (formerly known as Histogenics Corporation), together with its wholly owned subsidiaries (“Ocugen” or the “Company”), is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. The Company is located in Malvern, Pennsylvania, and manages its business as one operating segment.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen is developing OCU300, which is a small molecule therapeutic currently in Phase 3 development for the treatment of symptoms associated with ocular graft-versus-host disease ("oGVHD"). OCU300 has received orphan drug designation ("ODD") from the U.S. Food and Drug Administration ("FDA"), and it is the first and only product candidate to receive that designation for the treatment of symptoms associated with oGVHD. oGVHD is a severe chronic autoimmune disease that can result in light sensitivity, excessive ocular redness, severe ocular pain and, ultimately, vision impairment. OCU300 is formulated using our proprietary nanoemulsion technology, OcuNanoE—Ocugen’s ONE Platform™.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen is also developing a modifier gene therapy platform to generate therapies designed to fulfill unmet medical needs in the area of retinal diseases, including inherited retinal diseases. Ocugen's modifier gene therapy platform is based on nuclear hormone receptors ("NHRs"), which have the potential to restore homeostasis, the basic biological processes in the retina. Unlike single-gene replacement therapies, which only target one genetic mutation, the Company believes that its gene therapy platform, through its use of NHRs, represents a novel approach in that it may address multiple retinal diseases with one product. Ocugen's first gene therapy candidate, OCU400, received two ODDs from the FDA, one for the treatment of nuclear receptor subfamily 2 group E member 3 ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">") mutation-associated retinal diseases and the other for the treatment of centrosomal protein 290 ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CEP290</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">") mutation-associated retinal diseases. Ocugen is planning to initiate a Phase 1/2a clinical trial for OCU400 in 2021. Ocugen's second gene therapy candidate, OCU410, is being developed to utilize the nuclear receptor genes RAR-related orphan receptor A ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RORA</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">") for the treatment of dry age-related macular degeneration ("AMD"). This candidate is currently in preclinical development.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen is additionally in preclinical development for a novel biologic product candidate, OCU200. OCU200 is a novel fusion protein designed to treat diabetic macular edema ("DME"), diabetic retinopathy ("DR") and wet AMD. The Company expects to initiate a Phase 1/2a clinical trial for OCU200 in 2022, and plans to expand the therapeutic applications of OCU200 beyond DME, DR, and wet AMD to potentially include macular edema following retinal vein occlusion and myopic choroidal neovascularization.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Merger with Histogenics</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 27, 2019, the Company completed its reverse merger with Ocugen OpCo, Inc. (“OpCo”) in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of April 5, 2019, by and among Histogenics Corporation ("Histogenics"), OpCo and Restore Merger Sub, Inc., a wholly owned subsidiary of Histogenics (“Merger Sub”), as amended (the “Merger Agreement”), pursuant to which Merger Sub merged with and into OpCo, with OpCo surviving as a wholly owned subsidiary of Histogenics (the “Merger”). Immediately after completion of the Merger, Histogenics changed its name to Ocugen, Inc. and the business conducted by Ocugen, Inc. became the business conducted by OpCo. OpCo is deemed to be the accounting acquirer. Accordingly, the historical financial statements of OpCo became the Company’s historical financial statements, including the comparative prior periods. See Note 3 for additional information.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reverse Stock Split</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with, and immediately prior to the completion of the Merger, Histogenics effected a reverse stock split of the common stock, at a ratio of 1-for-60 (the ‘‘Reverse Stock Split’’). Under the terms of the Merger Agreement, the Company issued common stock to OpCo’s stockholders at an exchange rate of 0.4794 shares of common stock, after taking into account the Reverse Stock Split, for each share of OpCo’s common stock outstanding immediately prior to the Merger.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The capital structure, including the number of shares of common stock issued appearing in the condensed consolidated balance sheets for the periods presented, reflects that of Ocugen. All references in the condensed consolidated financial statements to the number of shares and per-share amounts of common stock have been retroactively restated to reflect the exchange rate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Going Concern</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes, and debt. The Company incurred net losses of approximately $3.9 million and $6.3 million for the three months ended March 31, 2020 and 2019, respectively. As of March 31, 2020, the Company had an accumulated deficit of $55.4 million and cash, cash equivalents and restricted cash totaling $3.3 million.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in its industry. The Company intends to continue its research and development efforts for its product candidates, which will require significant funding. If the Company is unable to obtain additional financing in the future or research and development efforts require higher than anticipated capital, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by raising additional capital through public and private placements of equity and/or debt, payments from potential strategic research and development arrangements, sale of assets, and licensing and/or collaboration arrangements with pharmaceutical companies or other institutions. Such financing may not be available at all, or on terms that are favorable to the Company. While management of the Company believes that it has a plan to fund ongoing operations, its plan may not be successfully implemented. Failure to generate sufficient cash flows from operations, raise additional capital through one or more financings, or appropriately manage certain discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of these factors, together with the anticipated increase in spending that will be necessary to continue to develop the Company’s products, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. The condensed consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.</span></div>
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-3900000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-6300000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55400000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3300000	USD
CY2020Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States (“GAAP”) and under the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim reporting. The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, that are necessary to present fairly the Company’s financial position, results of operations, and cash flows. The condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures of the Company normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC’s rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December 31, 2019, included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the "2019 Annual Report").</span></div>
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In preparing the condensed consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the estimation of clinical trial accruals and the valuation of share-based payment arrangements and embedded conversion features on the convertible notes.</span></div>
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3193188	USD
CY2020Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	7000000.0	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	308717	USD
CY2020Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151100	USD
CY2019Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	150625	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3344288	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	459342	USD
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-3943819	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-6312606	USD
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52627228	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4960552	shares
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.27
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12140719	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1394809	shares
CY2020Q1	ocgn	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	120092	USD
CY2019Q4	ocgn	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	271322	USD
CY2020Q1	ocgn	Accrued Liabilities Clinical AccruedLiabilitiesClinical	406213	USD
CY2019Q4	ocgn	Accrued Liabilities Clinical AccruedLiabilitiesClinical	421788	USD
CY2020Q1	ocgn	Accrued Liabilities Professional Fees AccruedLiabilitiesProfessionalFees	486395	USD
CY2019Q4	ocgn	Accrued Liabilities Professional Fees AccruedLiabilitiesProfessionalFees	917568	USD
CY2020Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	369499	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	624420	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1459	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	34947	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1383658	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2270045	USD
CY2019Q2	us-gaap	Shares Issued SharesIssued	100000	shares
CY2019Q2	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	1000000.0	USD
CY2019Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	12.41
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	13000000.0	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	222513	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	415202	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1400000	USD
CY2020Q1	ocgn	Number Of Equity Compensation Plans NumberOfEquityCompensationPlans	2	segment
CY2019Q4	ocgn	Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase In Shares To Be Issue Percentage ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage	0.04
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.42
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	47696	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	73273	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	21169	USD
CY2019Q1	us-gaap	Variable Lease Cost VariableLeaseCost	15848	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	68865	USD
CY2019Q1	us-gaap	Lease Cost LeaseCost	89121	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	302990	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	344574	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	176616	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	172310	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	117142	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	163198	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	293758	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	335508	USD
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M18D
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.076
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.076
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	144169	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	160909	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	11354	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	316432	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	22674	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	293758	USD
CY2020Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2020Q1	us-gaap	Lessee Finance Lease Discount Rate LesseeFinanceLeaseDiscountRate	0.076
CY2020Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	23856	USD
CY2020Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	3977	USD
CY2020Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	27833	USD
CY2020Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	1278	USD
CY2020Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	26555	USD
CY2019Q3	ocgn	Percentage Of Excess Common Stock On Pre Merger Financing Warrants One PercentageOfExcessCommonStockOnPreMergerFinancingWarrantsOne	0.0499
CY2019Q3	ocgn	Percentage Of Excess Common Stock On Pre Merger Financing Warrants Two PercentageOfExcessCommonStockOnPreMergerFinancingWarrantsTwo	0.0999
CY2019Q3	ocgn	Percentage Of Amount On Market Value For Failure To Issue Common Stock On Pre Merger Financing Warrants PercentageOfAmountOnMarketValueForFailureToIssueCommonStockOnPreMergerFinancingWarrants	0.020

Files In Submission

Name	View Source	Status
0001628280-20-007094-index-headers.html	Edgar Link	pending
0001628280-20-007094-index.html	Edgar Link	pending
0001628280-20-007094.txt	Edgar Link	pending
0001628280-20-007094-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ocgn-20200331.htm	Edgar Link	pending
ocgn-20200331.xsd	Edgar Link	pending
ocgn-20200331x10qxex104.htm	Edgar Link	pending
ocgn-20200331x10qxex105.htm	Edgar Link	pending
ocgn-20200331x10qxex106.htm	Edgar Link	pending
ocgn-20200331x10qxex311.htm	Edgar Link	pending
ocgn-20200331x10qxex312.htm	Edgar Link	pending
ocgn-20200331x10qxex321.htm	Edgar Link	pending
ocgn-20200331_cal.xml	Edgar Link	unprocessable
ocgn-20200331_def.xml	Edgar Link	unprocessable
ocgn-20200331_htm.xml	Edgar Link	completed
ocgn-20200331_lab.xml	Edgar Link	unprocessable
ocgn-20200331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OCGN
Ocugen, Inc. Stock $ocgn

2020 Q1 Form 10-Q Financial Statement

#000162828020007094 Filed on May 08, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN Ocugen, Inc. Stock $ocgn

2020 Q1 Form 10-Q Financial Statement

#000162828020007094 Filed on May 08, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN
Ocugen, Inc. Stock $ocgn